ReviewEuropean journal of immunology2016
Suppression of innate inflammation and immunity by interleukin-37.
Review in European journal of immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 1 synthesis or guideline pooled it, 217 citations in OpenAlex.
- Pooled it
- IL-37 and IL-38 in sepsis: immune-metabolic rheostats in a dynamic inflammatory continuum.Frontiers in immunology · 2026Review
- The diagnostic and immunomodulatory role of IL-37 in pediatric sepsis.Frontiers in immunology · 2026Article
- Neutrophil to lymphocyte ratio (NLR) and YKL-40 as potential markers for discriminating mycoplasma pneumoniae pneumonia from viral pneumonia in children.Open medicine (Warsaw, Poland) · 2026Article
- Interleukin-37 polymorphism (rs3811047) in Egyptian patients with ulcerative colitis.Molecular biology reports · 2025Article
- SIGIRR: An Orphan Receptor Mediating Anti-inflammatory Actions.Expert reviews in molecular medicine · 2025Review
- Interleukin-37 Suppresses the Function of Type 2 Follicular Helper T in Allergic Rhinitis.Biomedicines · 2025Article
- Interleukin-37 reduces lipopolysaccharide induced matrix metalloproteinase-9 in gingival epithelial cells.BMC oral health · 2025Article
- Interleukin-37 in respiratory diseases: molecular mechanisms and immune modulation.Frontiers in immunology · 2025Review
- Potential pro-tumour cytokine in oral squamous cellular carcinoma: IL37.Journal of cellular and molecular medicine · 2024Article
- Expanding Role of Interleukin-1 Family Cytokines in Acute Ischemic Stroke.International journal of molecular sciences · 2024Review
- The Protective Role of Interleukin-37 in Cardiovascular Diseases through Ferroptosis Modulation.International journal of molecular sciences · 2024Review
- IL-37d suppresses Rheb-mTORC1 axis independently of TCS2 to alleviate alcoholic liver disease.Communications biology · 2024Article
- Advanced glycation end product-modified low-density lipoprotein promotes pro-osteogenic reprogramming via RAGE/NF-κB pathway and exaggerates aortic valve calcification in hamsters.Molecular medicine (Cambridge, Mass.) · 2024Article
- Food-derived bioactive peptides potentiating therapeutic intervention in rheumatoid arthritis.Heliyon · 2024Review
- A chromatin-regulated biphasic circuit coordinates IL-1β-mediated inflammation.Nature genetics · 2024Article
- Ethnobotanical, Phytochemical, and Pharmacological Properties of the Subfamily Nepetoideae (Lamiaceae) in Inflammatory Diseases.Plants (Basel, Switzerland) · 2023Review
- A novel approach to achieving more efficient production of the mature form of human IL-37 in plants.Transgenic research · 2023Article
- The Complex Relationship between Hypoxia Signaling, Mitochondrial Dysfunction and Inflammation in Calcific Aortic Valve Disease: Insights from the Molecular Mechanisms to Therapeutic Approaches.International journal of molecular sciences · 2023Review
- Intestinal cell type-specific communication networks underlie homeostasis and response to Western diet.The Journal of experimental medicine · 2023Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 5 countries.
Funding
Abstract
IL-37 is unique in the IL-1 family in that unlike other members of the family, IL-37 broadly suppresses innate immunity. IL-37 can be elevated in humans with inflammatory and autoimmune diseases where it likely functions to limit inflammation. Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury. IL37-tg mice have reduced antigen-specific responses and dendritic cells (DCs) from these mice exhibit characteristics of tolerogenic DCs. Compared to aging wild-type (WT) mice, aging IL37-tg mice are protected against B-cell leukemogenesis and heart failure. Treatment of WT mice with recombinant human IL-37 has been shown to be protective in several models of inflammation and injury. IL-37 binds to the IL-18 receptor but then recruits the orphan IL-1R8 (formerly TIR8 or SIGIRR) in order to function as an inhibitor. Here, we review the discovery of IL-37, its production, release, and mechanisms by which IL-37 reduces inflammation and suppresses immune responses. The data reviewed here suggest a therapeutic potential for IL-37.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.